Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We review the latest literature on the neuropharmacological treatments for acquired nystagmus.Nystagmus may have a significant [corrected] impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.

Original publication

DOI

10.1136/practneurol-2011-000181

Type

Journal article

Journal

Pract Neurol

Publication Date

06/2012

Volume

12

Pages

147 - 153

Keywords

Amines, Aminopyridines, Baclofen, Cyclohexanecarboxylic Acids, Humans, Memantine, Nystagmus, Congenital, Nystagmus, Pathologic, Randomized Controlled Trials as Topic, Treatment Outcome, gamma-Aminobutyric Acid